<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>dendritic cell maturation &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/dendritic-cell-maturation/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 11:59:42 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>dendritic cell maturation &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Targeting the Interaction of Key Proteins: A New Avenue for Cancer Therapy</title>
		<link>https://bioengineer.org/targeting-the-interaction-of-key-proteins-a-new-avenue-for-cancer-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 14 May 2025 21:16:56 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[cancer therapy resistance]]></category>
		<category><![CDATA[dendritic cell maturation]]></category>
		<category><![CDATA[dendritic cell-mediated immunity]]></category>
		<category><![CDATA[immunotherapy resistance mechanisms]]></category>
		<category><![CDATA[STAT3 degraders in oncology]]></category>
		<category><![CDATA[STAT3-STAT5 interaction]]></category>
		<category><![CDATA[STAT3-STAT5 signaling balance]]></category>
		<category><![CDATA[targeted protein degradation]]></category>
		<category><![CDATA[targeted protein degradation therapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/targeting-the-interaction-of-key-proteins-a-new-avenue-for-cancer-therapy/</guid>

					<description><![CDATA[Immunotherapy has revolutionized cancer treatment by harnessing the body’s own immune system to identify and eradicate malignant cells. Among the various strategies employed, immune checkpoint inhibitors have shown promise by disrupting the molecular brakes that tumors impose upon immune cells, effectively unleashing a more potent anti-cancer response. These therapies work by blocking specific proteins that [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">245187</post-id>	</item>
	</channel>
</rss>
